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ABSTRACT 
Background: Lung cancer is one of the non-communicable diseases that have an increasing 
number of events that each year with a mortality rate of 18.4% and an incidence of 11.6%. One 
of management in the NSCLC is currently in the form of surgery and adjuvant therapy. 
However, there were weaknesses and limitations in care for its patients therefore development 
of curative therapy for NSCLC’s patients were needed.  The aim of this review is to learn and 
investigate about the potential of siRNA that is transfected into McD and folate receptors alpha-
conjugated gold nanoparticle encapsulation as a therapeutic opportunity that could be 
developed as a treatment in management of NSCLC.  
Method: The writing method used in this review article was the study method of literature.  
The used data comes from 45 of relevant literature sources and was arranged systematically in 
accordance with the topic of the problem discussed, along with the inclusion and exclusion 
criteria.  
Result: This treatment could increase gene transfection, siRNA biodistribution in organs, 
reduced KRAS, Bcl-2, and VEGF expression.  Moreover, siRNA had entered phase III clinical 
trials and FOLR1 antibodies were in phase II of clinical trials. 
Conclusion: Utilization of siRNA specifically was designed for three genes such for KRAS, 
VEGF and Bcl-2 which were three genes that played a role in the pathogenesis of NSCLC, 
could be the right modality choice for treatment of NSCLC. 
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Lung cancer is one of the non-
communicable diseases which occupies the top 
position as a cause of death with a percentage of 
18.4% of the number of cancer cases worldwide 
(GLOBOCAN, 2018). Based on research by De 
Groot et al (2012), lung cancer is dominated by 
men over the age of 50 years. Judging from the 
cause, as many as 80% of lung cancer’s deaths 
are caused by smoking. In fact, according to the 
US Centers for Disease Control and Prevention, 
exposure to Other People's Cigarette Smoke 
(AROL) causes 50,000 deaths each year. 
Moreover, the population of Indonesians who 
smoke is increasing. Based on data from 
Tobacco Atlas (2012), the number of cigarettes 
consumed in Indonesia increased from 182 
billion sticks to 260.8 billion. In addition to 
smoking, unhealthy lifestyles such as alcohol 
consumption and genetic factors also contribute 
to increasing the risk of lung cancer.34 
One type of lung cancer that accounts for 
more than 80% of all lung cancer cases is Non 
Small-cell Lung Carcinoma (NSCLC). The 
management of NSCLC therefore far depends 
on the condition of the patient's prognosis and 
staging. Patients who are in stage I, II, and IIIA 
generally undergo surgical procedures to 
remove the tumor. However, this can still cause 
recurrence in patients suffering from NSCLC 
type of adenocarcinoma with a greater mutation 
fraction and lead to a tendency for earlier 
metastases45. Besides surgery, there are 
adjuvant therapies, such as radiotherapy, 
chemotherapy, and target therapy. Radiotherapy 
is a therapeutic method used to reduce the size 
of the tumor, but the therapeutic efficacy is less 
than optimal because it is limited by systemic 
tumor progression, the presence of local or 
distant metastases, and tumor resistance itself. 16 
Similar to radiotherapy, chemotherapy also has 
high toxicity and side effects. 
The level of expression of KRAS, Bcl-2, 
and VEGF genes is a gene that can indicate the 
prognosis in NSCLC patients so that it becomes 
a biomarker that can be used as NSCLC curative 
therapy. The mutated KRAS activation becomes 
one of the signaling pathways that play a role in 
resistance to EGFR tyrosine kinase inhibitors 
(TKIs), as well as monoclonal antibodies4. High 
expression of Bcl-2 can prevent cancer cells 
from apoptosis.28 The VEGF plays a role in the 
progression of cancer through angiogenesis by 
stimulating vascular permeability of blood 
vessels and increasing extravasation of plasma 
proteins.14 
Small interfering RNA (siRNA) is part 
of RNAi (RNA interference) which has the 
ability to regulate gene expression, primarily in 
performing its function as gene silencing of 
specific molecules. siRNA will be designed 
specifically for the KRAS, Bcl-2, and VEGF 
genes as advanced curative therapy in NSCLC 
patients. However, challenges in administering 
siRNA therapy include instability in blood 
serum, accumulation in nonspecific tissue, and 
inefficient intracellular release25.Therefore an 
effective, safe, and capable carrier that increases 
the concentration of siRNA, is needed in the 
distribution of siRNA to the target cell so as to 
produce maximum efficacy.7 
McD technology (DNA minicircle) is a 
nonviral based vector that can be used in siRNA 
transfection. DNA minicircle is able to maintain 
the expression of genes carried 10-1000 times 
higher compared to conventional plasmids. 
However, gene transfection via McD is not 
single selective to the desired target cell. 
Therefore, McD-based siRNA administration 
will be encapsulated by gold nanoparticles 
(AuNP).23 
Gold nanoparticle (AuNP) is an 
encapsulation based on nanoparticle technology 
that can be used as a carrier of substances aimed 
at target cells. However, the distribution of 
siRNA by encapsulation of AuNP requires a 
specific ligand to facilitate siRNA to target the 
desired cell. Thus, AuNP will be conjugated 
with the alpha receptor Folate (FOLR1) 
antibody to form AuNP-FOLR1. FOLR1 is a 
protein that functions as a folate transporter and 
is overexpressed in lung cancer. The FOLR1 
antibody binds to the folate receptor and creates 
a ligand receptor complex that will later regulate 
signaling in cancer.2 
Methods 
 
The method that is used in writing this 
literature review is a literature review method 
where the data used comes from various 
239 
 
©2021, JEKK, All Right Reserved 
 
 
Sadvika., et al., JEKK. 6 (2) 2021 
 
relevant literature sources obtained from several 
search engines such as Pubmed, NCBI and 
Google Scholar. The literature obtained is then 
filtered based on inclusion and exclusion 
criteria. Inclusion criteria include journals 
discussing points on keywords, are research 
journals and article reviews and have a 
maximum time span of journals of the past ten 
years. While exclusion criteria include not 
containing information according to keywords, 
journals are protocol only articles and have a 
range of more than ten years. Furthermore, from 
all selected journals, 45 journals were found that 
fit the inclusion and exclusion criteria. The data 
obtained are in the form of quantitative and 
qualitative data which are then compiled 
systematically and in accordance with each 
topic discussed so that there are groups that 




Specific SiRNA silencing of KRAS, 
Bcl-2, and VEGF genes will be delivered by 
DNA minicircle vectors with significant gene 
transfection. Chabot, et al (2012) in their study 
used the same number of copies for each 
experiment. The level of gene expression was 
analyzed with green-fluorescent protein (GFP). 
McD (MC-GFP) and conventional plasmid (p-
GFP) construction are injected into the tibial 
cranial mouse. Mice were injected with MC-
GFP or p-GFP and Co-transfection TurboFP635 
plasmids as internal controls. The results of the 
MC-GFP GFP fluorescence analysis in all 
muscle samples were 2.4-10.8 times higher than 
the p-GFP. The fluorescence ratio of GFP and 
internal control (TurboFP635 shows that MC-
GFP causes gene expression 2.5–4 times higher 
than p-GFP (2.6 times ± 0.5 increase on day 8 
and 4 times increase ± 0.9 on day 18)3. 
Research in vivo Reuveni et al, (2011) 
regarding comparisons between actively 
designed AuNP biodistribution with 
conjugation of EGFR antibodies, passively with 
anti-immunoglubulin G conjugation and six 
hours post administration without conjugation 
as control. The results showed a significant 
increase in organ biodistribution in AuNP 
conjugated EGFR antibodies compared to the 
other two groups in tumor tissue. In line with 
this, Takeuchi, et al (2018) research on PEG 
conjugated AuNP biodistribution. Results show 
that PEG conjugated AuNP is significantly 
higher in the lungs starting from six hours post-
injection and increasing organ accumulation for 
up to 48 hours.37 
At 24, 48 and 96 hours after siRNA 
nanoparticle injection, cell lysate was prepared 
for analysis using qPCR and Western blot. The 
level of KRAS silencing was assessed in all cells 
by immunobloting techniques. The results of 
measurement of mRNA level with qPCR 
showed a significant decrease in KRAS 
expression starting from the analysis in the first 
24 hours with a constant expression level of up 
to 96 hours. In vivo studies by Pecot, et al (2014) 
showed a decrease in KRAS expression using 
KRAS siRNA and NC siRNA constructs as 
controls administered intravenously in rats for 
four weeks showed a reduction in luminescence 
by 81% compared to control siRNA (P <0.01) 
(P <0.01) (P <0.01).27 
In vivo research by Tekedereli et al. 
(2013) to determine the effect of silencing the 
Bcl-2 gene in mice with MDA-MB-231 tumor 
cells in orthotopic xenograft models was carried 
out by NL-Control-siRNA and NL-Bcl-2-
siRNA administration at a dose of 0.075 and 
0.15 mg siRNA / kgBB IV via the tail vein. 
Tumors were removed on the 2nd, 4th and 6th 
day after injection and analyzed with 
densitometry analysis bands. Significantly 
decreased Bcl-2 protein expression using NL-
Bcl-2-siRNA compared to NL-Control-siRNA 
at the same dose.38 
Research Yuan et al. (2015) to determine 
the effect of VEGF silencing with siRNA in 
vivo. C57BL / 6 mice were injected with Lewis 
Lung Carcinoma (LLC) subcutaneously. When 
the tumor reached ± 0.5 cm in diameter, samples 
were injected with OH-antitumoral control, OH-
VEGF, ppp-control or ppp-VEGF at a dose of 
20 μg for each injection twice a week for two 
weeks of administration. After two migraines it 
was found that the number of blood vessels due 
to VEGF induced angiogenesis in LLC showed 
a significant reduction with OH-VEGF and ppp-
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Discussion 
Lung cancer cells have an increased 
proliferation activity associated with the KRAS 
gene (Rini, et al, 2011). The KRAS gene 
(Kirsten Rat Sarcoma) which encodes the RAS 
protein, binds to the guanosine nucleotides, 
namely guanosin diphosphate (GDP) and 
guanosin triphosphate (GTP). RAS protein will 
be activated by transforming GDP into GTP 
Furthermore, inactivation of RAS protein occurs 
through the activity of the GTPase enzyme that 
hydrolyzes GTP to GDP.19 
Intrinsic pathway apoptosis is induced 
by mitochondrial stress resulting in the release 
of proapoptotic factors such as cytochrome c 
and AIF from mitochondrial intermembrane 
(Wong, 2011). The release was regulated by the 
Bcl-2 family, namely BAX and BAD (Sari, 
2018). Cytochrome c released into the 
cytoplasm binds to Apaf-1 and forms the 
Caspase Recruitment Domain (CARD). The 
CARD compound forms an apoptosome 
complex that activates the initiator caspase, 
caspase-9, which in turn activates the executor 
caspase by converting procaspase-3 to caspase-
3. In NSCLC lung cancer, excessive expression 
occurs in Bcl-2 so that cancer cells are able to 
overcome the apoptotic signals from Myc and 
RAS.33,41 
In its development, the pathogenesis of 
cancer is related to angiogenesis. Angiogenesis 
is initiated by vascular endothelial growth factor 
(VEGF).6,21 One mechanism that is able to 
regulate VEGF expression is hypoxia. Hypoxia 
inducible factor-1 (HIF-1) is the most important 
mediator of the hypoxic response.13 Cytokines 
and growth factors are also able to regulate the 
expression of angiogenic factors in cancer cells 
so that it will indirectly stimulate angiogenesis, 
such as HER2 and EGFR, COX -2 and platelet-
derived growth factors (PDGFs).42 
SiRNA therapy is a new anticancer 
approach that has undergone phase III clinical 
trial involving ± 6500 cancer patients.5 SiRNA-
based therapy has potential as a cancer therapy, 
including NSCLC lung cancer. SiRNA therapy 
also has several advantages over traditional 
pharmaceutical drugs. Moreover, siRNA is a 
form of RNA interference (RNAi) which is a 
post-transcription gene silencing mechanism. 
The work of siRNA is done by triggering the 
degradation of mRNA by attaching double-
stranded RNA (dsRNA) into the target cell. 
RNAi is able to inhibit the expression of genes 
contained in specific sequences through the 
termination of mRNA that has a homologous 
short sequence.29 
Gene silencing therapy method with 
siRNA is a promising method. However, siRNA 
has a weakness, namely the instability of siRNA 
molecules while in the cell due to the activity of 
nuclease enzymes which break down the 
structure of siRNA into its nucleotide bases, 
molecules that are hydrophilic so that they are 
easily degraded, molecules that will undergo 
endosomal breakdown by liposomes, molecules 
that must enter the cell's nucleus to carry out its 
functions, and the structure of the DNA and 
DNA are folded and protected so that siRNA 
cannot function optimally as gene silencing-
based therapy. The mechanism of action of 
siRNA is at the stage of transcription and post-
transcription of the protein by binding 
specifically to the target mRNA so that it causes 
downregulation, even silencing targeted 
genes.11 
Minicircle DNA (McD) is a nonviral 
transfection vector derived from minicircle 
producer plasmids (pMC). Plasmids are 
extrachromosomal DNA found in living cells 
and are able to replicate autonomously.23 McD 
production comes from a special parental 
plasmid strain of E. coli which is engineered to 
cause the parent plasmid to breed and produce 
minicircles. McD is produced conditionally by 
the expression of the aseC31 integrase induced 
by intramolecular recombination (cis-). Then, 
McD was planted in a special strain of E. coli 
host bacteria with an arabinose-induced system 
to express integrase 31C31 and I-SceI 
endonuclease simultaneously. McD is a vector 
that is easier to produce, inexpensive, stable, and 
safer than ordinary plasmid methods. McD's 
advantage over conventional plasmids is that it 
can increase transfection because of its smaller 
size. McD does not contain inflammatory 
sequences, sequences of replication sources, is 
free of expression of viral antigens, does not 
contain antibiotic resistance markers or bacteria 
from replication so they have a high level of 
security in the body. McD can increase 
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transgene expression 10-1000 times higher than 
conventional DNA plasmids.1 
Gold nanoparticles (AuNP) are 
nanoparticles with different properties from 
inert gold in nature and are synthesized from 
natural materials, biomaterial egg shells and 
sunlight.9 AuNP is nano-sized (1 nm-8 μm) so 
that it is able to cross cell membranes and nuclei 
to interact with DNA, shows excellent 
penetration into cells, can increase cellular 
absorption efficiency and delivery to reach 
target tissue. As a cancer therapy, AuNP offers 
a nano platform material for ultrasensitive 
detection of biomolecules, killing cancer cells 
with hyperthermal treatment, labeling cells and 
proteins, easily conjugated so as to suppress side 
effects, and able to deliver therapeutic agents in 
cells.24 Another advantage of AuNP is its high 
surface area so it is easily modified for therapies 
that target specific genes or cells, are non-
cytotoxic, safe, environmentally friendly, 
increase half life, and are biocompatible with the 
body.15 AuNP can deliver hydrophilic and 
hydrophobic drugs because of its characteristic 
that monolayers are able to change the structural 
properties of lipid molecules that interact 
directly with the surface of nanoparticles (Lan, 
et al., 2013). Later, AuNP will be conjugated 
with the FOLR1 (Folate Receptor alpha) 
antibody to make specific drugs work on targets 
related to NSCLC lung cancer pathogenesis. 
Folate receptor alpha (FOLR1) is a 
membrane protein receptor that is bound to 
glycosylphosphatidylinositol (GPI) and has 
high expression in lung cancer. FOLR1 shows 
very low or even non-expression on normal 
cells. FOLR1 can be translocated to the nucleus 
and act as a transcription factor and binds to the 
cis-regulator element. Through this mechanism, 
FOLR1 can directly regulate the expression of 
key development genes in cancer cells. FOLR1 
has also been shown to inhibit caveolin-1 so that 
it supports the growth and proliferation of tumor 
cells that are not dependent on the port and 
increase the development of cancer. The 
presence of anti-FOLR1 as a target for cancer 
therapy has been widely developed and has 
entered a phase II clinical trial.2 
McD's construction begins with the 
preparation of plasmid minicircles made by 
inserting DNA elements: KanR genes which are 
enclosed in the attB and attP binding sites of the 
31C31 integrase bacteriophage, as well as 
endonuclease A fragments amplified using PCR 
to form the pMC.HFIX or pMC.RSV.HAAT 
binding site. ZYCY10P3S2T strain will be 
added. The PCR primers used were 5′-
TCCTGTTACCAGTGGCTGCT and 5′-
AGTTCGGTGTAGGTCGTTCG. After that, 
bacterial amplification was carried out by 
combining 100 μl of culture for every 400 ml of 
TB containing Kan (50 μg / ml) and continued 
incubation for 16-18 hours with a pH of ~ 6.5. 
The mixture is combined with culture and used 
to isolate McD vectors using a plasmid 
purification kit.23 
SiRNA construction is carried out using 
PCR with the basic principle of cutting short 
hairpin RNA (shRNA) from a plasmid vector 
into 2 short RNA chains that are complementary 
to each other. First the KRAS sequence is 
incorporated in a siRNA encoding DNA 
template consisting of a double-stranded class 
III T7 promoter then transcribed with R7 
polymerase T7 to produce a single chain RNA 
transcript containing the target sequence of the 
KRAS gene. Transcripts were incubated to form 
the structure of the hairpin shRNA, then cut 
using the enzyme dicon RNA endonuclease. 
The process is then repeated using VEGF and 
Bcl-2 sequences. The siRNA transfection 
method is using McD vectors which are cut with 
endonuclease restriction enzymes, then KRAS, 
VEGF, and Bcl-2 specific siRNAs are inserted 
into McD, and the bonds are strengthened with 
ligase enzymes.26 
AuNP is formed through the green 
biosynthesis method which uses natural 
biomaterial eggshell (ESM) membrane. This 
method is done by soaking HAuCl4 solution 
without using a reducing agent (Epanchintseva, 
2019). Next, AuNP is stabilized using 
heterobifunctional PEG with thiol groups at one 
end and one of the carboxyl (HS-EG (8) -CH2) 
2-COOH, PEG-COOH) or azide (HS- (CH2) 3-
CONH-EG groups (6) - (CH2) 2-N3, PEG-N3) 
on the other hand, then incubated for 16 hours, 
and purified by centrifugation. The conjugation 
of the isolated siRNA chain was removed 
through incubation of AuNP (5nm) with the 
siRNA chain in the DEPC and SDS 0.028% then 
a 0.1 M NaCl concentration was added and then 
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quantified with fluorescence using a GelRed 
intercalator.35 
FOLR1-conjugated gold nanoparticles 
can be synthesized with a linker such as 
glutathione as a stabilizer and an agent for 
coupling. There are steps proposed in making 
this conjugation, namely glutathione that binds 
to the surface of AuNP through cysteine groups. 
Then, the carboxyl group from glutathione will 
be activated through N, N-
dicyclochexylcarbodiimide (DCC) and N-
hydroxysuccin-imide (NHS). Finally, folate / 
glutathione / AuNP is formed through the 
reaction between the carboxyl glutathione group 
and the amine group of folic acid.32,45  
Administrative modalities will be given 
intravenously (IV) because they provide direct 
access to blood circulation by injection and can 
be spread easily into the tissues.40 In addition, 
IV administration of gold nanoparticles has a 
lower toxicity content compared to other 
administrative channels. 
The modality administered in IV causes 
the modality not to pass through absorption and 
directly circulates in the blood vessels. 
Furthermore, the modality will be distributed to 
the organs of the body. The modality of siRNA 
encapsulation AuNP reaches peak accumulation 
in organs ± 4-12 hours after injection and 
accumulates constantly after 24 hours (Takeuchi 
et al, 2018). Accumulation is directly 
proportional to the increased elimination of 
AuNP through urine so that there is no 
deposition in organs. PEG conjugated AuNP 
causes modalities to be undetectable by the 
immune system to avoid endocystosis and 
siRNA degradation that is transfected through 
McD as it passes through the endosomal 
pathway.37 McD-siRNA will go to the nucleus 
to replicate and carry out its function. AuNP 
which has brought McD-siRNA to target cells is 
excreted via exocytosis to be re-channeled into 
blood vessels and accumulated in the kidneys 
after six hours after injection to be excreted in 
urine. McD-siRNA will continue to be 
expressed until the expression of the target gene 
namely KRAS, Bcl-2 and VEGF is lost from the 
target cell. Once the gene expression is stopped, 
siRNA will be naturally degraded by the body.17 
The therapeutic effect of siRNA is seen 
through a decrease in downstream signals and 
inhibition of NSCLC lung cancer cell 
proliferation. Research by Pecot et al. 2014 
shows that siRNA is able to silence the KRAS 
gene. KRAS is a gene that encodes the function 
of cell proliferation and express RAS proteins. 
The siRNA molecule is able to inactivate the 
RAS protein by reducing the affinity of the 
picomolar GTPase binding and cellular 
concentration of GTP so that the binding 
process can be inhibited. This causes the 
hydrolysis of GDP to GTP can also be 
stopped.27 
The results of the study by Geng, et al., 
2013 showed that siRNA was able to induce 
apoptosis by increasing the ratio of Bax / Bcl-2 
and at the same time silencing Bcl-2. Increased 
expression of BAX protein which is pro-
apoptosis causes impaired permeability 
resulting in cytochrome c and AIF release from 
mitochondrial intermembrane. Cytochrome c 
released into the cytoplasm will bind to Apaf-1 
and form CARD. Combined several CARDs 
then form an apoptosome complex that will 
activate the initiator caspase, namely caspase-9 
so that caspase-3 activation occurs as the 
executor caspase.33 
Research Jafari, et al., (2016) showed that 
siRNA was able to inhibit the expression of 
VEGF and HIF-α factors so as to prevent 
angiogenesis by decreasing the regulation of 
molecules involved in angiogenesis, such as: 
neurophilin, angiogenin, interleukin 6 and 8, 
MCP-1 and TGF- β. The mechanism of 
inhibition of VEGF expression, including 
VEGF-A, is initiated by activating PPARγ 
which then inactivates the phosphatidylinositol 
3-kinase / protein kinase B (AKT) pathway. The 
unactivated phosphatidylinositol 3-kinase / 
protein kinase B (AKT) pathway will result in 
decreased transcriptional mRNA transcription 
and expression of VEGF-A resulting in 





The modality construction mechanism starts 
from making McD, then constructing siRNA 
using PCR, inserting specific KRAS, VEGF, 
and Bcl-2 siRNA into McD, making AuNP 
through the green biosynthesis method, and 
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continuing with conjugation of FOLR1 to 
AuNP. Modality administration is given 
intravenously (IV) because it gives direct access 
to blood circulation. After doing its work, AuNP 
will be excreted via exocytosis, while McD-
siRNA will continue to be expressed until the 
expression of the target gene, KRAS, Bcl-2 and 
VEGF, is lost from the target cell. The 
mechanism of action of the modality as NSCLC 
management, namely inhibiting cell 
proliferation by silencing the KRAS gene, 
inducing apoptosis by increasing the Bax / Bcl-
2 ratio and simultaneously silencing Bcl-2, as 
well as inhibiting the expression of VEGF and 
HIF-α factors so as to prevent angiogenesis. The 
clinical effect of the modality is to increase gene 
transfection, increase the biodistribution of 
siRNA in organs, decrease the expression of 
KRAS, Bcl-2, and VEGF. Moreover, siRNA has 
entered clinical trials up to phase III and the 
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